Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.2% |
| 2 | Technology | 14.19% |
| 3 | Financials | 12.33% |
| 4 | Consumer Staples | 10.22% |
| 5 | Industrials | 9.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TOWR
2376
DELISTED
Tower International, Inc.
TOWR
| $1.59M | ﹤0.01% |
70,825
+41,125
| +138% | +$992K |
|
2377
Valhi
VHI
$457M
| $1.59M | ﹤0.01% |
44,400
-738
| -2% | -$29.3K |
|
|
FNGN
2378
DELISTED
Financial Engines, Inc.
FNGN
| $1.59M | ﹤0.01% |
+43,400
| New | +$1.73M |
|
2379
Arq
ARQ
$101M
| $1.58M | ﹤0.01% |
173,000
+112,400
| +185% | +$1.05M |
|
|
CORV
2380
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
| $1.58M | ﹤0.01% |
350,713
+97,300
| +38% | +$353K |
|
|
AMFW
2381
DELISTED
AMEC Foster Wheeler plc
AMFW
| $1.58M | ﹤0.01% |
263,300
-66,000
| -20% | -$443K |
|
|
MRT
2382
DELISTED
MedEquities Realty Trust, Inc.
MRT
| $1.58M | ﹤0.01% |
+125,400
| New | +$1.5M |
|
2383
Ultralife
ULBI
$127M
| $1.58M | ﹤0.01% |
219,500
+69,400
| +46% | +$425K |
|
|
LUMO
2384
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
| $1.58M | ﹤0.01% |
23,878
+18,556
| +349% | +$2.3M |
|
2385
Gyre Therapeutics
GYRE
$689M
| $1.58M | ﹤0.01% |
45,290
+36,520
| +416% | +$1.31M |
|
2386
Aegon
AEG
$14B
| $1.58M | ﹤0.01% |
389,853
-117,960
| -23% | -$462K |
|
2387
Landmark Bancorp
LARK
$196M
| $1.58M | ﹤0.01% |
80,174
+6,515
| +9% | +$129K |
|
|
HEES
2388
DELISTED
H&E Equipment Services
HEES
| $1.57M | ﹤0.01% |
77,100
+67,700
| +720% | +$1.42M |
|
|
BEBE
2389
DELISTED
Bebe Stores Inc
BEBE
| $1.57M | ﹤0.01% |
264,230
+33,400
| +14% | +$159K |
|
2390
Larimar Therapeutics
LRMR
$446M
| $1.57M | ﹤0.01% |
37,258
+22,241
| +148% | +$1.14M |
|
|
BSF
2391
DELISTED
Bear State Financial, Inc.
BSF
| $1.56M | ﹤0.01% |
165,163
-17,311
| -9% | -$160K |
|
2392
Nicolet Bankshares
NIC
$3.75B
| $1.56M | ﹤0.01% |
28,500
+16,800
| +144% | +$845K |
|
2393
Webster Financial
WBS
$12.8B
| $1.54M | ﹤0.01% |
29,531
-205,600
| -87% | -$10.4M |
|
|
NWY
2394
DELISTED
New York & Co Inc
NWY
| $1.54M | ﹤0.01% |
1,117,500
+88,000
| +9% | +$135K |
|
|
LADR
2395
Ladder Capital
LADR
$1.28B
| $1.54M | ﹤0.01% |
114,930
+47,600
| +71% | +$682K |
|
|
ZAGG
2396
DELISTED
ZAGG Inc Common Stock (Delaware)
ZAGG
| $1.54M | ﹤0.01% |
+178,200
| New | +$1.42M |
|
|
GPIC
2397
DELISTED
Gaming Partners International Corporation
GPIC
| $1.54M | ﹤0.01% |
128,800
+700
| +0.5% | +$7.21K |
|
2398
DNOW Inc
DNOW
$2.98B
| $1.53M | ﹤0.01% |
95,300
-405,200
| -81% | -$6.9M |
|
2399
OFG Bancorp
OFG
$2.25B
| $1.53M | ﹤0.01% |
153,170
-85,700
| -36% | -$900K |
|
2400
Mueller Water Products
MWA
$3.99B
| $1.53M | ﹤0.01% |
130,800
-336,100
| -72% | -$3.86M |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.